Brain-Computer Interfaces in China – From Laboratory to Commercial Reality

On July 13, 2026, a paralyzed patient at Huashan Hospital in Shanghai became the first person in the world to receive a commercially approved brain-computer interface implant. This is the story of how China is leading the BCI revolution.

I. Introduction: The BCI Revolution Comes of Age

Brain-computer interfaces (BCIs) have long been the stuff of science fiction — a technology that allows the human brain to communicate directly with external devices, bypassing the need for muscles or nerves. For decades, BCI research was confined to laboratories, with occasional demonstrations in controlled settings.

That era is over. In 2026, China has transformed BCI from a research curiosity into a commercial reality. With the world's first regulatory approval of an implantable BCI system, the first commercial implant surgery, and a rapidly expanding pipeline of BCI technologies, China has emerged as the undisputed global leader in this transformative field.

This article chronicles the key milestones in China's BCI journey in 2026, explores the technologies behind the breakthroughs, and examines the clinical and commercial implications of this historic advancement.

I. NEO: The World's First Commercially Approved Implantable BCI

Regulatory Milestone: NMPA Class III Certification

On March 13, 2026, China's National Medical Products Administration (NMPA) granted Class III medical device certification to the NEO Implantable Brain-Computer Interface System for Hand Motor Function Compensation, developed by Borikang Medical Technology (博睿康医疗).

This certification made NEO the world's first commercially approved implantable BCI product — a historic moment that placed China at the forefront of a technology that many experts believe will revolutionize the treatment of paralysis, stroke, and neurodegenerative diseases.

Technology Overview

The NEO system comprises three key components:

• Implantable device — a coin-sized electrode array positioned on the dura mater (the outermost layer of the meninges) via a minimally invasive procedure. The device detects neural signals from the motor cortex associated with intended hand and arm movements.
• Wireless transceiver — transmits neural signals from the brain to an external processing unit without the need for transcutaneous wires, reducing infection risk.
• External actuator — a pneumatic glove that translates decoded neural signals into precise, graded hand movements for grasping and releasing objects.

The NEO system uses a subdural (epidural) electrode placement rather than penetrating electrodes, which significantly reduces the risk of damage to brain tissue while maintaining high signal fidelity.

II. The First Commercial BCI Implant: A Historic Surgery

On July 13, 2026, a team of neurosurgeons at Huashan Hospital (Fudan University, Shanghai) performed the first commercial BCI implant surgery using the NEO system.

The patient, who had been paralyzed from a cervical spinal cord injury, was the first person in the world to receive a commercially approved brain-computer interface.

Patient Outcomes

Within weeks of the implant, the patient was able to:

• Grasp and release objects using the NEO pneumatic glove, controlled entirely by neural signals
• Perform fine motor tasks — picking up a cup, holding a pen, and turning pages
• Demonstrate sustained signal quality with no degradation or device-related complications in the initial follow-up period

Dr. Xu Yuhua, a leading neurosurgeon at Huashan Hospital and a member of the surgical team, described the procedure as "a turning point in the history of neurorehabilitation."

III. The BCI Landscape in China: Beyond NEO

While NEO has captured global attention, it is just one component of a rapidly expanding BCI ecosystem in China.

Ultra-High-Channel Invasive BCI: Zhimeng Medical

In May 2026, Beijing Zhimeng Medical (智冉医疗) announced the initiation of China's first ultra-high-channel-count invasive BCI registry trial, featuring a system with over 100 recording channels — substantially more than NEO's 16-channel design.

The trial aims to evaluate the safety and efficacy of a fully implantable, high-density microelectrode array for patients with severe motor impairment, with preliminary data expected in 2027.

Semi-Invasive BCI: "Beinao No. 1"

The "Beinao No. 1" (北脑一号) semi-invasive BCI system has completed nearly 30 human implants, accumulating over 70,000 cumulative hours of safe operation. This system uses electrodes placed on the cortical surface without penetrating brain tissue, balancing signal quality with safety.

Non-Invasive BCI: EEG-Based Systems

Several Chinese companies are developing non-invasive BCI systems using electroencephalography (EEG) for applications including:

• Stroke rehabilitation — guiding robotic exoskeletons for upper-limb training
• Sleep monitoring and cognitive assessment
• Augmentative communication for patients with locked-in syndrome

IV. Market Growth and Investment

China's BCI sector has seen explosive growth in investment and activity in 2026.

Metric	Value
Projected BCI market value (China, 2028)	6.14 billion yuan (~$904 million)
Financing events (Jan–May 2026)	Over 30 (exceeding 2025 total)
BCI companies in China (2026)	50+ across implantable, semi-invasive, and non-invasive segments
Government policy designation	"Future industry" in Government Work Report; included in 15th Five-Year Plan (2026–2030)

The Chinese government has designated BCI a "future industry" in the Government Work Report and included it in the outline of the 15th Five-Year Plan (2026–2030), signaling strong policy support for the sector's development.

V. Clinical Applications: Beyond Paralysis

While motor restoration for paralysis patients has been the primary focus of BCI development, Chinese researchers are exploring a broader range of clinical applications:

• Stroke rehabilitation — using BCI-guided robotic therapy to promote neuroplasticity and recovery of function
• Epilepsy monitoring and prediction — detecting seizure precursors through continuous neural recording
• Neuropsychiatric disorders — closed-loop stimulation systems for depression, OCD, and Parkinson's disease
• Prosthetic control — direct neural control of advanced prosthetic limbs

VI. Regulatory and Ethical Considerations

The commercialization of implantable BCI devices raises important regulatory and ethical questions. China has taken a proactive approach to addressing these issues:

• NMPA guidelines for BCI medical devices were issued in early 2025, establishing clear regulatory pathways
• Ethical review committees are required for all BCI clinical trials, with specific attention to informed consent and patient autonomy
• Data privacy and security — neural data is classified as protected health information with strict handling requirements

VII. What This Means for International Patients

For international patients considering BCI therapy in China:

• Access to the world's only commercially approved implantable BCI — the NEO system is currently available only in China
• World-class surgical expertise — Chinese neurosurgeons have accumulated extensive experience in BCI implantation
• Cost advantage — BCI implantation in China is significantly more affordable than comparable procedures in the U.S. or Europe
• Clinical trial opportunities — next-generation BCI systems are available through clinical trials at leading Chinese hospitals

Conclusion

2026 will be remembered as the year brain-computer interfaces moved from science fiction to clinical reality. With the world's first commercially approved implantable BCI system, the first commercial BCI implant surgery, and a rapidly expanding pipeline of next-generation technologies, China has established itself as the global leader in this revolutionary field.

As one industry analyst put it: "China is not just participating in the BCI revolution — it is defining it."